INSM
HealthcareInsmed Incorporated · Biotechnology · $23B
What is Insmed Incorporated?
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients living with serious and rare diseases.
Insmed generates revenue primarily through ARIKAYCE, an approved treatment for a rare lung infection. The company is also advancing a pipeline targeting bronchiectasis and rare pulmonary disorders, aiming to expand its commercial footprint in underserved patient populations.
Founded in 1988 and headquartered in Bridgewater, New Jersey.
- ARIKAYCE — approved therapy for Mycobacterium avium complex lung disease
- Brensocatib — oral investigational treatment for bronchiectasis and neutrophil-mediated diseases
- Treprostinil Palmitil Inhalation Powder — inhaled therapy in development for pulmonary arterial hypertension
Is INSM a Good Stock to Buy?
UQS Score rates INSM as Below Average overall.
Growth stands out as a strong pillar, reflecting meaningful pipeline momentum and commercial expansion potential. The Risk pillar also rates as Good, suggesting the company's risk profile is relatively manageable for a clinical-stage biopharmaceutical.
Quality rates as Weak, and Valuation is Elevated — meaning the market may already be pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does INSM pay dividends?
No — Insmed Incorporated does not currently pay a dividend.
Insmed does not currently pay a dividend. As a biopharmaceutical company with an active pipeline, capital is directed toward research, clinical development, and commercialization rather than shareholder distributions.
When does INSM report earnings?
Insmed reports earnings on a quarterly cadence, typical for US-listed equities.
Results each quarter tend to reflect ARIKAYCE commercial trends alongside pipeline development costs. Investors watch closely for updates on Brensocatib trial progress and any shifts in operating expenses.
For the most recent quarter's results, see Insmed's investor relations page.
INSM Price History
+473.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Insmed Incorporated?
Based on Insmed Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Insmed do?
Insmed is a biopharmaceutical company that develops and commercializes therapies for rare and serious diseases. Its approved product, ARIKAYCE, treats a rare lung infection, while its pipeline targets bronchiectasis and pulmonary arterial hypertension.
Does INSM pay dividends?
No, Insmed does not pay a dividend. The company reinvests available capital into clinical development and the commercialization of its rare-disease therapies.
When does INSM report earnings?
Insmed follows a standard quarterly reporting schedule. For exact dates, visit the company's investor relations page directly.
Is INSM a good stock to buy?
UQS Score rates INSM as Below Average overall. Growth rates as Strong and Risk as Good, but Quality is Weak and Valuation is Elevated. The complete pillar breakdown is available to Pro members on uqs-score.com.
Is INSM overvalued?
The UQS Valuation pillar for INSM is rated Elevated, suggesting the current price reflects high expectations for pipeline success. Investors should weigh this against the company's growth profile.
Is INSM a long-term quality indicator?
As a long-term quality indicator, INSM's profile is mixed. Strong Growth and Good Risk are positives, but Weak Quality and Elevated Valuation present meaningful hurdles for long-horizon investors seeking durable fundamentals.
What is INSM's market cap bracket?
Insmed is classified as a large-cap company, placing it among the larger publicly traded biopharmaceutical firms despite not yet being consistently profitable.
Who founded Insmed?
Insmed was founded in 1988. Founding and leadership history is widely publicly available through the company's official investor relations materials.
Unlock Full INSM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
- ✓Access full financial metrics and trend data
- ✓Compare INSM against sector peers on a standardized scoring framework
- ✓Get the complete analyst view available to Pro members
Pro Analysis
INSM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 43.0 | 8.7 | 40.0 | 85.6 | 71.8 | 19.3 | +0.2 |
| May 21, 2026 | 42.8 | 8.7 | 40.0 | 85.6 | 71.8 | 18.2 | 0.0 |
| May 19, 2026 | 42.8 | 8.7 | 40.0 | 85.6 | 71.8 | 18.4 | -0.4 |
| May 15, 2026 | 43.2 | 8.7 | 40.0 | 85.6 | 71.8 | 20.6 | +0.2 |
| May 14, 2026 | 43.0 | 8.7 | 40.0 | 85.6 | 71.8 | 19.8 | -0.8 |
| May 12, 2026 | 43.8 | 8.7 | 40.0 | 85.6 | 71.8 | 24.6 | -2.4 |
| May 7, 2026 | 46.2 | 8.7 | 40.0 | 85.6 | 72.1 | 40.3 | -0.1 |
| May 3, 2026 | 46.3 | 8.7 | 40.0 | 85.6 | 72.1 | 40.9 | +0.1 |
| Apr 28, 2026 | 46.2 | 8.7 | 40.0 | 85.6 | 72.1 | 40.6 | 0.0 |
| Apr 26, 2026 | 46.2 | 8.7 | 40.0 | 85.6 | 72.1 | 40.8 | +0.2 |
INSM — Pillar Breakdown
Quality
— 8.7/100 (25%)Insmed Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 85.6/100 (20%)Insmed Incorporated is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 71.8/100 (15%)Insmed Incorporated maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 20.5/100 (15%)Insmed Incorporated appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 40/100 (25%)Insmed Incorporated possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for INSM.
Score Composition
Financial Data
More Stock Analysis
How is the INSM UQS Score Calculated?
The UQS (Unified Quality Score) for Insmed Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Insmed Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Insmed Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.